In addition, a recent phase II basket study of talazoparib in advanced solid tumors with diverse DNA damage repair alterations, including germline and somatic BRCA1/2 and other homologous recombination genes, demonstrated clinical benefit in a subset of patients, further supporting the concept of targeting HRD beyond traditional tumor types (37). Here, BRCA1 is linked to neoplasm.